Business Wire

  1. Precision BioSciences Announces Clearance Of Investigational New Drug Application By The U.S. FDA For First-In-Class PBGENE-HBV Designed To Eliminate Root Cause Of Chronic Hepatitis B 3/17/2025

    Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PBGENE-HBV.

  2. Xeris Announces Approval Of Supplemental New Drug Application (sNDA) Of Gvoke VialDx (Glucagon) For Use As A Diagnostic Aid 3/17/2025

    Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

  3. BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering Of Groundbreaking Software With Customizable Interface For AI-Driven Drug Discovery 6/10/2024

    ImmunoPrecise Antibodies Ltd. (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.

  4. Every Cure Deploys BioPhy's Artificial Intelligence Platform To Accelerate Its Mission Of Repurposing Drugs For Untreated Diseases 4/30/2024

    BioPhy, an innovative AI drug development company, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

  5. X-Chem Acquires Glamorous AI — Immediately Creating A Leader In DEL-Powered AI Solutions 10/28/2021

    X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery.

  6. Pfizer Establishes Precision Medicine Research Collaboration With Medco 11/1/2011
    Pfizer Inc. (NYSE: PFE) announced recently that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes
  7. Spectrum Pharmaceuticals To Present At The Rodman & Renshaw 10th Annual Global Healthcare Investment Conference 11/5/2008
    Spectrum Pharmaceuticals, Inc., announced today that an overview of the Company’s business strategy will be presented at the Rodman & Renshaw Annual 10th Annual Global Healthcare Investment Conference, on Tuesday, November 11, 2008, at 12:00 p.m. Eastern
  8. AgilityBio And Advinus Announce Partnership To Introduce Digital Pathology Services In Pre Clinical Research 11/5/2008
    AgilityBio, a division of BioImagene Inc, and Advinus Therapeutics, a TATA enterprise, announced a partnership that will enable providing imaging services in conjunction with preclinical development services offered by Advinus
  9. Progenics Selects Small-Molecule Hepatitis C Drug Candidate For Clinical Development 11/4/2008
    Progenics Pharmaceuticals, Inc.,today announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection
  10. Akorn, Inc. Announces FDA Approval Of Adenosine Injection USP, 3 mg/mL 11/3/2008
    Akorn, Inc., today announced that the U.S. Food and Drug Administration has granted approval for Akorn’s Abbreviated New Drug Application (ANDA) for Adenosine Injection USP, 3 mg/mL